Upregulated TRIM32 correlates with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma
Upregulated TRIM32 correlates with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma
复制标题
TRIM32 上调与肝细胞癌细胞增殖增强和预后不良相关
DOI：
10.1007/s11010-016-2793-z
复制
发表时间：
2016-10-01
影响因子：
4.3
通讯作者：
Ni, Runzhou
中科院分区：
文献类型：
--
作者：
Cui, Xiaopeng;Lin, Zhipeng;Ni, Runzhou
肝细胞癌（HCC）是原发性肝癌的主要类型，也是世界范围内第六大常见的人类恶性肿瘤。然而，肝癌发生的分子机制仍不清楚。对于HCC患者，不仅缺乏有效的治疗靶点，而且缺乏预测或预后生物标志物。在本文中，我们报道了TRIM 32在肝癌组织和肝癌细胞系中明显上调。其表达模式与HCC患者的组织学分级、肿瘤大小和HBsAg呈正相关。TRIM 32表达是HCC患者总生存时间的重要预测因子。此外，TRIM 32在细胞中的过表达加速了G1-S期转变，促进了细胞增殖速率，并诱导了HCC患者对奥沙利铂的耐药性。这些结果提示TRIM 32可能在肝癌的发生发展中起重要作用。TRIM 32可能成为探讨肝癌发病机制的新方向。
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer and the sixth most prevalent human malignancies worldwide. However, the molecular mechanisms underlying hepatocarcinogenesis remain unclear. For HCC patients, there is not only a lack of effective therapeutic targets but also a lack of predictive or prognostic biomarkers. In this article, we reported that TRIM32 was obviously upregulated in HCC tumor tissues and HCC cell lines. Its expression patterns were positively correlated with histological grade, tumor sizes, and HBsAg of HCC patients. TRIM32 expression was a significant predictor for the overall survival time of HCC patients. Moreover, the overexpression of TRIM32 in cells accelerated the G1-S phase transition, promoted cell proliferation rates, and induced the resistance of HCC patients to oxaliplatin. All these findings suggest that TRIM32 might play important roles in the hepatocarcinogenesis. TRIM32 could be a novel direction to explore the mechanism underlying HCC pathogenesis.